1 2 3 4 5

Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets

Assoumou, Lambert; Cozzi-Lepri, Alessandro; Brun-Vézinet, Françoise; More

AIDS . 24(3):365-371, January 28, 2010.

Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy

Greub, Gilbert; Cozzi-Lepri, Alessandro; Ledergerber, Bruno; More

AIDS . 16(14):1967-1969, September 27, 2002.

Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals

Phillips, Andrew N.; Miller, Veronica; Sabin, Caroline; More

AIDS . 15(18):2379-2384, December 7, 2001.

Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir

Kirk, Ole; Mocroft, Amanda; Pradier, Christian; More

AIDS . 15(8):999-1008, May 25, 2001.

The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study

Mocroft, Amanda; Phillips, Andrew N.; Miller, Veronica; More

AIDS . 15(2):201-209, January 26, 2001.

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

Miller, Veronica; Sabin, Caroline; Hertogs, Kurt; More

AIDS . 14(18):2857-2867, December 22, 2000.

The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load

Miller, Veronica; Sabin, Caroline A.; Phillips, Andrew N.; More

AIDS . 14(14):2129-2136, September 29, 2000.

Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples

Hertogs, Kurt; Bloor, Stuart; Kemp, Sharon D.; More

AIDS . 14(9):1203-1210, June 16, 2000.

HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy

Miller, Veronica; Ait-Khaled, Mounir; Stone, Chris; More

AIDS . 14(2):163-171, January 28, 2000.

The M184 V mutation in HIV‐1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross‐resistance to nucleoside analogue RT inhibitors

Miller, Veronica; Stürmer, Martin; Staszewski, Schlomo; More

AIDS . 12(7):705-712, May 7, 1998.

Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients.

Staszewski, Schlomo; Miller, Veronica; Rehmet, Sibylle; More

AIDS . 10(5):F1-F7, May 1996.

1 2 3 4 5